TO THE EDITOR FLT3 (FMS-like tyrosine kinase) is a member of the class b receptor tyrosine kinase (RTKb) receptor family, which includes FLT1, FMS, PDGFRb, and KIT. 1 The RTK family contains an extracellular domain that consists of five immunoglobulin-like repeats, 2,3 a transmembrane domain (TM), a juxtamembrane domain (JM), two intracellular tyrosine kinase domains (TK1 and TK2) divided by a kinase insert domain (KI), and a C-terminal domain ( Figure 1 ). FLT3 is expressed at high levels either in hematologic malignancies, including 70-100% of acute myelogenous leukemia (AML), or in leukemia and lymphoma cell lines. 2 AML patients contain two specific somatic mutations of the FLT3 gene and the first studied FLT3 mutation is an internal tandem duplication (ITD) mutation. 3 Recently, an ITD of the FLT3 gene (FLT3-ITD) was found in 20-25% of adult AML. 3, 4 FLT3-ITD mutations typically result from the duplication and tandem insertion of a portion of the JM region of the FLT3 wildtype gene. 5 Secondly, D835 is a missense mutation of the aspartic acid residue at position 835 in the activation loop of FLT3, and has also been described in AML, and these mutations are located in the activation loop of the second TKD of FLT3. 2, 5 Above all, from the clinical standpoint, FLT3-ITD often emerges during relapse or progression in patients with AML or myelodysplastic syndrome (MDS), suggesting that genetic instability might be associated with its occurrence.
3 FLT3-ITD occurs in about 15% of secondary AML cases and may be associated with disease progression or relapse. 2 However, on the other hand, some patients lost their FLT3 mutation at relapse. 6 Many studies have reported that FLT3-ITD mutations are associated with leukocytosis, irrespective of age and an association with an increased percentage of bone marrow or peripheral blood blasts at presentation. Like FLT3-ITD, D835 mutations of FLT3 also induce constitutive tyrosine phosphorylation and enhance cell proliferation.
5 D835 mutations usually occur independently of ITD mutations, 3 but they are not mutually exclusive and the presence of concurrent D835 and ITD mutations has been reported in AML. 7 In this study, we have examined the above-described FLT3 gene mutations of two types in refractory AML patients who showed poor remission during primary induction chemotherapy, and we discuss the relationships between the mutations and patient prognosis.
In all, 11 refractory AML patients from 105 newly diagnosed AML were included in this study. Among them, four patients showed remarkable FLT3-ITD mutations, and clinical profiles of them are shown in Table 1 . We collected bone marrow and peripheral blood samples from all patients before and after our standard induction chemotherapy. Mononuclear cells were enriched and RNA was extracted. A 1 mg portion of RNA was reverse transcribed using a first-strand cDNA synthesis kit for RT-PCR. RT-PCR was performed and the amplified PCR products were electrophoresed in 2% agarose gels with ethidium bromide staining. ITD DNA fragments were detected as two bands of higher molecular weight than the wild-type FLT3 fragment (at 240 and 330 bp). These higher molecular weight fragments were then isolated and sequenced. We amplified mutated regions at residue D835 by RT-PCR using previously described primers ( Table 2 ). Amplified products were digested and visualized under ultraviolet light with ethidium bromide staining. In alleles containing a D835 mutation, the 113 bp PCR fragment remained, but in wild-type alleles, it was digested to produce fragments of 68 and 45 bp. ITD was examined by amplifying the JM domain from exons 11 and 12.
6,7 ITD DNA fragments were detected as high molecular weight bands migrating above that of wild-type FLT3 fragment Figure 1 Structure of FLT3. The FLT3 gene consists of five extracellular immunoglobulin-like domains, a TM domain, a JM domain, and an interrupted kinase domain (TK1 and TK2). The ITD mutation is located at the JM domain. Missense mutation of D835 is usually located in the TK2 domain. The arrows display the ITD primers and D835 primers. Table 1 Clinical characteristics of refractory AML patients investigated in this study 
F: forward; R: rear. DNA. Sequence analysis was carried out on the wild-type band of 240 and 330 bp, and differently sized PCR products were identified in ITD-positive patients (Figure 2 ). PCR products were recovered using a gel extraction kit. In our experiments, ITD mutations of between 40 and 105 bases occurred in four patients and were located in the frame of the JM domain as expected. ITD mutations were detected in four of the 11 cases as higher molecular weight bands than the wild-type fragments. Sequence analysis of ITD mutation samples showed tandem duplications, confirming and characterizing the ITD in these samples. Two of four patients showed many base duplications: 51 bases were duplicated from 128 to 178 in one patient and 42 bases were repeated from 109 to 150 in the second patient. When the mutation in the first patient's sequence was translated to amino acids, it did not effect the amplified sequence to be translated to codon unlike the wild-type. The duplicated sequence was translated and we found a new amino acid in the second patient, indicating that the duplicated sequence had altered the translated product. A third patient showed duplication and tandem insertion, and ITD was increased by 45 bases, that is, five nucleotides from 80 to 84 were tandem inserted and 40 bases from 85 to 124 were duplicated. The duplicated and tandem insertion sequences corresponded to the new amino acid in the third patient. The fourth patient had a duplication and tandem insertion based on the 330 bp band. The total number of bases increased by 105 from 153 to 257. Three nucleotides were tandem inserted from 153 to 155 unlike the wild type. Together, 102 bases were duplicated from 156 to 257. Also in the fourth patient, the duplicated and tandem insertion sequences corresponded to the new amino acid in effect. D835 wild type was digested to fragments of 68 and 45 bases ( Figure 3 ). However, D835 mutation was not found in the patients involved in this experience. We studied 11 adult patients with AML who were primarily refractory to standard chemotherapy: four patients (36%) showed FLT3-ITD mutations and the four ITD mutants sequenced showed different duplications. The mutant sequences found in these four patients were all novel ( Table 3) . Two of these four patients had duplication mutations, and the other two patients showed ITD mutations with both duplication and tandem insertion. Sequence analysis of ITD mutation bands revealed in-frame duplications between 40 and 105 bases in the JM domain. In one of the four patients, the ITD mutation did not cause a transcription error, but in the other three patients the mutations corresponded to amino-acid changes. Mutations in Correspondence the JM domain, or activating loop mutations, result in the constitutive activation of FLT3 kinase, which is strongly associated with leukocytosis and poor prognosis in AML patients. Four patients with ITD showed poor treatment response as has been reported. 2 The ITD mutations of AML patients have shown variable rates in other studies. Also our four ITD mutation patients contained the JM domain. However, interestingly, we could not find a D835 mutation in this study, but there were many kinds of duplications at different locations with different sizes.
Some studies have been undertaken on FLT3 mutations in paired samples at diagnosis and relapse and have also shown that the mutation can be unstable and the mutation patterns can change. These studies support the idea that mutations are more likely to represent secondary events during the process of leukemogenesis rather than being primary initiating events. 7, 8 In addition, unlike another report, 8 we found heterogeneous levels of FLT3 expression during chemotherapy at different times in this study (data not shown). In contrast to the ITD mutation, no mutation of D835 was found in patients involved in our experiment, and no patient showed a combination of both ITD mutation and D835 mutation. Refractory AML is heterogeneous and a more complex disease entity and has several clinical characteristics such as a poor response to chemotherapy, a rapid cell cycle, and excessive leukemic proliferation, which are explained by the 'multiple hit theory' or other complex forms of specific gene mutations. Therefore, unlike the optimistic responses to the noble 'target therapy' using STI-571(Glivec R ) in patients with chronic myelogenous leukemia, AML is frequently highly resistant to conventional chemotherapy, and the recently trialed target therapies in patients with FLT3-ITD mutations. Our study demonstrates that various FLT3 mutations in patients with refractory AML may be a factor of poor clinical outcome. Although further aggressive investigation is needed on the exact function and the molecular pathways involved, we suggest that the discovery of these novel mutations may lead us to a highly tailored and more accurate patient stratification. 
